[The Estimated Economic Impact of Cardiovascular and Diabetes Mellitus Complications 2019-2028]

Overview

Journal Rev Med Inst Mex Seguro Soc

Specialty General Medicine

Date 2023 Feb 16

PMID 36795992

Authors

Francisco Javier Pico-Guzman

Olga Georgina Martinez-Montanez

Enrique Ruelas-Barajas

Mauricio Hernandez-Avila

Affiliations

Soon will be listed here.

Abstract

Background: In Mexico, diabetes mellitus (DM) and diseases cardiovascular, register an upward trend.

Objective: To estimate the number of complications due to cardiovascular events (CVD) and complications derived from DM (CDM) accumulated in beneficiaries of the Mexican Institute of Social Security (IMSS) from 2019 to 2028, as well as the expense for medical and economic benefits in a scenario baseline and one of change in metabolic profile due to lack of medical follow-up during the COVID-19 pandemic.

Material And Methods: The number of CVD and CDM was estimated from 2019, with a 10-year risk projection using the ESC CVD Risk Calculator and United Kingdom Prospective Diabetes Study, considering risk factors registered in the institutional databases.

Results: From 2019 to 2028, cumulative CVD cases were estimated at 2 million and those of CDM in 960 thousand, with an impact on medical spending of 439,523 million pesos and on the economic benefits of 174,085 millions. When considering the COVID-19 pandemic, CVD events and CDM increased by 589 thousand, with an increase in spending of 93,787 million pesos for medical care and 41,159 million for economic benefits.

Conclusions: Without a comprehensive intervention in the management of CVD and CDM, the cost by both diseases will continue to increase, with financial pressures getting older.

Citing Articles

Mortality and Years of Life Lost From Cardiometabolic Diseases in Mexico: National and State-Level Trends, 1998-2022.

Agudelo-Botero M, Davila-Cervantes C Public Health Rep. 2025; :333549241308166.

PMID: 39871530 PMC: 11775945. DOI: 10.1177/00333549241308166.

References

You Y, Doubova S, Pinto-Masis D, Perez-Cuevas R, Borja-Aburto V, Hubbard A . Application of machine learning methodology to assess the performance of DIABETIMSS program for patients with type 2 diabetes in family medicine clinics in Mexico. BMC Med Inform Decis Mak. 2019; 19(1):221. PMC: 6852791. DOI: 10.1186/s12911-019-0950-5. View

Palacio-Mejia L, Hernandez-Avila J, Hernandez-Avila M, Dyer-Leal D, Barranco A, Quezada-Sanchez A . Leading causes of excess mortality in Mexico during the COVID-19 pandemic 2020-2021: A death certificates study in a middle-income country. Lancet Reg Health Am. 2022; 13:100303. PMC: 9230439. DOI: 10.1016/j.lana.2022.100303. View

Castellano J, Narula J, Castillo J, Fuster V . Promoting cardiovascular health worldwide: strategies, challenges, and opportunities. Rev Esp Cardiol (Engl Ed). 2014; 67(9):724-30. DOI: 10.1016/j.rec.2014.01.023. View

Borja-Aburto V, Gonzalez-Anaya J, Davila-Torres J, Rascon-Pacheco R, Gonzalez-Leon M . Evaluation of the impact on non-communicable chronic diseases of a major integrated primary health care program in Mexico. Fam Pract. 2015; 33(3):219-25. DOI: 10.1093/fampra/cmv049. View

Lopez Santi R, Marquez M, Piskorz D, Saldarriaga C, Lorenzatti A, Wyss F . Ambulatory Patients with Cardiometabolic Disease and Without Evidence of COVID-19 During the Pandemic. The CorCOVID LATAM Study. Glob Heart. 2021; 16(1):15. PMC: 7894376. DOI: 10.5334/gh.932. View

Bogataj Jontez N, Novak K, Kenig S, Petelin A, Jenko Praznikar Z, Mohorko N . The Impact of COVID-19-Related Lockdown on Diet and Serum Markers in Healthy Adults. Nutrients. 2021; 13(4). PMC: 8066004. DOI: 10.3390/nu13041082. View

Rodriguez Bolanos R, Reynales Shigematsu L, Jimenez Ruiz J, Juarez Marquezy S, Hernandez Avila M . [Direct costs of medical care for patients with type 2 diabetes mellitus in Mexico micro-costing analysis]. Rev Panam Salud Publica. 2011; 28(6):412-20. DOI: 10.1590/s1020-49892010001200002. View

Lopez Sanchez G, Lopez-Bueno R, Villasenor-Mora C, Pardhan S . Comparison of Diabetes Mellitus Risk Factors in Mexico in 2003 and 2014. Front Nutr. 2022; 9:894904. PMC: 9280272. DOI: 10.3389/fnut.2022.894904. View

Doubova S, Leslie H, Kruk M, Perez-Cuevas R, Arsenault C . Disruption in essential health services in Mexico during COVID-19: an interrupted time series analysis of health information system data. BMJ Glob Health. 2021; 6(9). PMC: 8413469. DOI: 10.1136/bmjgh-2021-006204. View

10.

Arsenault C, Gage A, Kim M, Kapoor N, Akweongo P, Amponsah F . COVID-19 and resilience of healthcare systems in ten countries. Nat Med. 2022; 28(6):1314-1324. PMC: 9205770. DOI: 10.1038/s41591-022-01750-1. View

11.

Stratton I, Adler A, Neil H, Matthews D, Manley S, Cull C . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258):405-12. PMC: 27454. DOI: 10.1136/bmj.321.7258.405. View

12.

Freudenberg N, Lee K, Buse K, Collin J, Crosbie E, Friel S . Defining Priorities for Action and Research on the Commercial Determinants of Health: A Conceptual Review. Am J Public Health. 2021; 111(12):2202-2211. PMC: 8667845. DOI: 10.2105/AJPH.2021.306491. View

13.

Kaye A, Okeagu C, Pham A, Silva R, Hurley J, Arron B . Economic impact of COVID-19 pandemic on healthcare facilities and systems: International perspectives. Best Pract Res Clin Anaesthesiol. 2021; 35(3):293-306. PMC: 7670225. DOI: 10.1016/j.bpa.2020.11.009. View

14.

Rivas-Gomez B, Almeda-Valdes P, Tussie-Luna M, Aguilar-Salinas C . DYSLIPIDEMIA IN MEXICO, A CALL FOR ACTION. Rev Invest Clin. 2018; 70(5):211-216. DOI: 10.24875/RIC.18002573. View

15.

. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021; 42(25):2439-2454. PMC: 8248998. DOI: 10.1093/eurheartj/ehab309. View

16.

Rosas-Peralta M, Attie F . [Cardiovascular disease. First cause of death in adults in Mexico and worldwide]. Arch Cardiol Mex. 2007; 77(2):91-3. View

17.

Reynoso-Noveron N, Mehta R, Almeda-Valdes P, Rojas-Martinez R, Villalpando S, Hernandez-Avila M . Estimated incidence of cardiovascular complications related to type 2 diabetes in Mexico using the UKPDS outcome model and a population-based survey. Cardiovasc Diabetol. 2011; 10:1. PMC: 3023678. DOI: 10.1186/1475-2840-10-1. View

18.

Campos-Nonato I, Hernandez-Barrera L, Oviedo-Solis C, Ramirez-Villalobos D, Hernandez-Prado B, Barquera S . . Salud Publica Mex. 2022; 63(6, Nov-Dic):692-704. DOI: 10.21149/12851. View

19.

Hernandez-Avila M, Gutierrez J, Reynoso-Noveron N . [Diabetes mellitus in Mexico. Status of the epidemic]. Salud Publica Mex. 2014; 55 Suppl 2:S129-36. View

20.

Lugo-Palacios D, Cairns J, Masetto C . Measuring the burden of preventable diabetic hospitalisations in the Mexican Institute of Social Security (IMSS). BMC Health Serv Res. 2016; 16:333. PMC: 4970294. DOI: 10.1186/s12913-016-1593-1. View